Un purpura thrombopénique amégacaryocytaire acquis qui cache une leucémie aigue myéloblastique

Eddou, Hicham; Ali, Z. Hadj; Khalloufi, A.; Sina, Mohammed; Mahtat, Mehdi; Doghmi, Kamal; Mikdame, M.; Moudden, Mohamed Karim; Baaj, M. El

doi:10.11604/pamj.2017.26.32.9215

Cited by 4 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the 242 ITP patients, URI occurred in 52 cases, with an incidence rate of 21.49%, which was basically consistent with the results of domestic and foreign studies [15]. In this study, the age, using glucocorticoid, smoking, platelet count, serum CRP level, and lymphocyte subsets CD 4 + and CD 8 + were all influencing factors of ITP patients developing uppersickness within half a year after diagnosis.…”

Section: Discussionsupporting

confidence: 90%

A Nomogram Model for Individualized Prediction of the Risk of Respiratory Tract Infection within Six Months after Diagnosis in Patients with Primary Immune Thrombocytopenia

Wei

Pan

Luo

et al. 2022

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

The risk factors of upper respiratory tract infection (URI) within 6 months after diagnosis in patients with idiopathic thrombocytopenic purpura (ITP) were analyzed, and the nomogram model was established and verified, with 242 and 50 ITP patients as the training and validation set, respectively. The patients were followed up for six months after the diagnosis of ITP. The clinical data of patients were collected, and the risk factors of URI in ITP patients within six months after diagnosis were analyzed using univariable, followed by multivariable logistic regression. Among the 242 ITP patients in the training set, 52 cases (21.49%) had URI, including 24 cases of viral infection, 11 cases of Mycoplasma pneumoniae infection, and 17 cases of bacterial infection. Logistic regression analysis showed that advanced age, use of glucocorticoid, smoking history, platelet count, serum CRP level, and lymphocyte subsets CD4+ and CD8+ were all risk factors for ITP patients to develop symptoms within six months after diagnosis ( P < 0.05 ). Using the above five indicators, a nomogram prediction model was built for URI occurrence in patients with ITP within half a year after diagnosis, and the results showed an AUC, a sensitivity, and a specificity of 0.936 (95% CI: 0.878-0.983), 0.942, and 0.865, respectively. The nomogram model was internally verified by the bootstrap method for 500 self-sampling times, and the prediction of the calibration curve was in high consistency with the real results. External validation of the nomogram model resulted in an AUC, a sensitivity, and a specificity of 0.890 (95% CI: 0.757-0.975), 0.949, and 0.727, respectively. The nomogram model of URI in ITP patients within half a year after diagnosis based on logistic regression analysis has good discrimination and prediction accuracy. This provides important guidance value for individualized prediction of URI in ITP patients.

show abstract

Section: Discussionsupporting

confidence: 90%

A Nomogram Model for Individualized Prediction of the Risk of Respiratory Tract Infection within Six Months after Diagnosis in Patients with Primary Immune Thrombocytopenia

Wei

Pan

Luo

et al. 2022

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

show abstract

“…Low platelet counts are also seen in most acute leukemias of non-AMKL type, acute myeloid leukemia, and lymphoid leukemia, 28 which are often complicated by the clinical feature of acquired amegakaryocytic thrombocytopenia. 29,30 It is usually thought the low platelet count results from the disruption of megakaryocytic differentiation and defective thrombopoiesis in the leukemic microenvironment. 31 In our study, in 7 cases, most megakaryocytes exhibited a damaged cell structure, such as vacuolization, autophagosomes, secondary and necrosis (Fig.…”

Section: Acute Leukemia Of Non-amkl Typementioning

confidence: 99%

Ultrastructural alterations of megakaryocytes in thrombocytopenia: A review of 43 cases

Eyden

Dong

et al. 2021

Blood Science

View full text Add to dashboard Cite

Thrombocytopenia is a frequent occurrence in a variety of hematopoietic diseases; however, the details of the mechanism leading to low platelet count remain elusive. Megakaryocytes are a series of progenitor cells responsible for the production of platelets. Alterations in megakaryocytes in the bone marrow are a causative factor resulting in thrombocytopenia in varied diseases. Based on ultrastructural analysis of incidentally encountered megakaryocytes in 43 patients with blood diseases marked by low platelet counts, electron micrographs demonstrated that aberrant megakaryocytes predominated in idiopathic thrombocytopenic purpura, aplastic anemia, and myelodysplastic syndrome; autophagy, apoptosis, and cellular damage in megakaryocytes were a prominent feature in aplastic anemia. On the other hand, poorly differentiated megakaryocytes predominated in acute megakaryoblastic leukemia (AMKL) although damaged megakaryocytes were seen in non-AMKL acute leukemia. This paper documents the ultrastructural alterations of megakaryocytes associated with thrombocytopenia and reveals distinctive features for particular blood diseases. A comment is made on future avenues of research emphasizing membrane fusion proteins.

show abstract

Cytarabine/daunorubicin

2017

Reactions Weekly

View full text Add to dashboard Cite

Un purpura thrombopénique amégacaryocytaire acquis qui cache une leucémie aigue myéloblastique

Cited by 4 publications

References 6 publications

A Nomogram Model for Individualized Prediction of the Risk of Respiratory Tract Infection within Six Months after Diagnosis in Patients with Primary Immune Thrombocytopenia

A Nomogram Model for Individualized Prediction of the Risk of Respiratory Tract Infection within Six Months after Diagnosis in Patients with Primary Immune Thrombocytopenia

Ultrastructural alterations of megakaryocytes in thrombocytopenia: A review of 43 cases

Cytarabine/daunorubicin

Contact Info

Product

Resources

About